The University of North Carolina at Chapel Hill

University of North Texas

Liquidia Technologies, Inc.

Robby A Petros

Joseph Desimone

Matthew Craig Parrott

Andrew J Murphy

The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug.

Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials

The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile &#x2014;Si-A-C&#x2014; groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C&#x2550;O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.

Growing community of inventors

Denton, TX, United States of America

Robby A Petros